In an unprecedented collaboration, tuberculosis (TB) experts from the U.S. and North Korea joined forces in 2008 to establish the state’s first lab for detecting drug-resistant tuberculosis. The medical professionals at Stanford’s Bay Area TB Consortium (BATC) launched the project with the North Carolina-based humanitarian group Christian Friends of North Korea and NTI’s Global Health and Security Initiative to “fill a critical gap in North Korea’s TB control program,” according to BATC director Sharon Perry.
NTI awarded $230,000 to Stanford’s proposal for the new lab in Pyongyang, and the funds purchased a World Health Organization-recommended inventory of lab equipment.
The rare collaboration that led to the development of the lab followed a dramatic resurgence in tuberculosis cases in North Korea after the famines of the 1990s. Between 2006 and 2008, the number of TB cases doubled to 344 per 100,000 people, posing a direct threat to North Korea’s neighbors.
Technicians in the new lab will be able to test for drug-resistant strains of TB that could not be detected by the North Koreans’ outdated method for diagnosis. The old testing method only identified about one-half of all cases because it could not detect drug-resistant strains.
Transforming the International Dialogue on Biological Threats
Library of Congress
New Tuberculosis Lab Developed in North Korea with Support from NTI’s Global Health and Security Initiative
North Korea's first laboratory for drug-resistant tuberculosis (TB) is developed in collaboration with U.S. doctors and TB experts.